You have 9 free searches left this month | to do more

parsaclisib

Parsaclisib is a drug used to treat Lymphoma, Advanced Malignancies, B-Cell Malignancies, and other conditions. Parsaclisib is being actively studied in 20 studies and prior, has been studied in 5.

Top SponsorsTop SitesTop Investigators
Incyte CorporationHospital Universitario Virgen Del RocioJohn Reneau
Incyte Biosciences Japan GKHospital Clinico Universitario de SalamancaJunning Cao, MD
Fudan UniversityTel Aviv Sourasky Medical CenterYanyan Liu
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
Not yet recruiting
  • PI3Kδ Inhibitor
  • +3 more
  • (no location specified)
2022-02-10
Feb 10, 2022
H
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021
I
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Not yet recruiting
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • parsaclisib
  • +2 more
  • (no location specified)
2022-02-07
Feb 7, 2022
O
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-07
Oct 7, 2021
I
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Recruiting
  • B-Cell Malignancies
  • Parsaclisib
  • +3 more
  • Birmingham, Alabama
  • +28 more
2022-03-30
Mar 30, 2022
U
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer - 2020
Withdrawn
  • Breast Cancer
  • +3 more
  • Parsaclisib
  • (no location specified)
2020-11-02
Nov 2, 2020
I
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
Active, not recruiting
  • Advanced Malignancies
  • parsaclisib
  • Tustin, California
  • +3 more
2022-03-14
Mar 14, 2022
I
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. - 2022
Completed
  • Advanced Malignancies
  • parsaclisib
  • Rialto, California
  • +4 more
2022-03-28
Mar 28, 2022
I
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Not yet recruiting
  • Mantle Cell Lymphoma
  • parsaclisib
  • +3 more
  • (no location specified)
2022-02-14
Feb 14, 2022
I
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Birmingham, Alabama
  • +38 more
2022-04-05
Apr 5, 2022
I
A Study of INCB050465 in Primary Sjögren's Syndrome - 2020
Completed
Has Results
  • Primary Sjögren's Syndrome
  • Parsaclisib
  • Miami, Florida
  • +3 more
2021-08-11
Aug 11, 2021
I
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Active, not recruiting
  • Lymphoma
  • Parsaclisib
  • Aichi, Japan
  • +5 more
2022-01-24
Jan 24, 2022
I
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Recruiting
  • Non Hodgkins Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Aichi, Japan
  • +4 more
2022-01-24
Jan 24, 2022
M
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Recruiting
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • +13 more
  • Scottsdale, Arizona
  • +2 more
2021-08-19
Aug 19, 2021
I
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Recruiting
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +48 more
2022-03-30
Mar 30, 2022
I
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) - 2021
Completed
  • B-Cell Malignancies
  • Parsaclisib
  • +5 more
  • Birmingham, Alabama
  • +6 more
2021-05-03
May 3, 2021
I
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Active, not recruiting
  • Autoimmune Hemolytic Anemia
  • Parsaclisib
  • Washington, District of Columbia
  • +12 more
2021-12-14
Dec 14, 2021
I
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
Withdrawn
  • Pemphigus Vulgaris
  • Parsaclisib
  • (no location specified)
2019-09-11
Sep 11, 2019
I
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) - 2021
Completed
  • Lymphoma
  • Parsaclisib
  • +2 more
  • Gilbert, Arizona
  • +20 more
2021-12-01
Dec 1, 2021
I
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Recruiting
  • Lymphoma
  • parsaclisib
  • Anjo, Japan
  • +29 more
2022-02-23
Feb 23, 2022
I
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Active, not recruiting
  • B-cell Lymphoma
  • Parsaclisib
  • +3 more
  • Tucson, Arizona
  • +20 more
2022-03-29
Mar 29, 2022
I
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Recruiting
  • Myelofibrosis
  • +3 more
  • parsaclisib
  • +2 more
  • Anchorage, Alaska
  • +155 more
2022-04-06
Apr 6, 2022
I
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Active, not recruiting
Has Results
  • Lymphoma
  • Parsaclisib
  • Phoenix, Arizona
  • +82 more
2022-01-14
Jan 14, 2022
I
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Recruiting
  • Myelofibrosis
  • +3 more
  • parsaclisib
  • +2 more
  • Berkeley, California
  • +178 more
2022-03-22
Mar 22, 2022
I
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) - 2021
Completed
Has Results
  • Lymphoma
  • Parsaclisib
  • Birmingham, Alabama
  • +69 more
2022-02-28
Feb 28, 2022